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We are very pleased that Quintana and Woolley (1) have engaged with the issues raised in 
our review (2); we believe that the field is best advanced by frank exchanges that identify 
issues of concern and ways to resolve them. We address the points raised in the order that 
they raise them. 
Quintana and Woolley cite three meta-analyses as supporting the ability of intranasal 
oxytocin to alter cognition. While we had suggested the possibility of publication bias in the 
literature on intranasal oxytocin (reflecting widespread concern about publication bias in both 
clinical and biological research), these meta-analyses indeed reported no evidence for this. 
However, Walum et al. (3) recently re-analysed the studies covered by these meta-analyses. 
They concluded that the studies were seriously underpowered, and argue that this is true 
generally of studies with intranasal oxytocin. Given such low power, they argue that ~80% of 
attempts to replicate any given study should fail to achieve statistical significance. They 
conclude that the relative absence of negative findings in the literature suggests that either 
publication bias is present, or that the excess of positive findings results from questionable 
research practices. 
 
Quintana and Woolley were surprised that we cited one of their studies (4) as evidence that 
intranasal oxytocin has no effect on patients with schizophrenia or healthy volunteers. We 
should not have cited that study so simplistically, and apologise.  In that study, Woolley et al. 
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gave oxytocin intranasally to schizophrenic patients and healthy controls, and tested them 
with the Reading the Mind in the Eyes Test (RMET) and The Awareness of Social Inference 
Test (TASIT). They found no significant effect on either test in healthy volunteers, and no 
effect on the RMET in schizophrenic patients. The TASIT test has three parts; they found an 
effect only in the third part, which addresses ‘controlled social cognition’ rather than the 
‘automatic social cognition assessed by other test elements. Their failure to find an effect on 
automatic social cognition was a primary outcome, as previous studies had reported effects 
on automatic processes, but we should not have neglected their positive finding. Quintana 
and Woolley state that this has been reported independently by other groups, citing Davis et 
al (5), who also used the third part of TASIT. However, Davis et al. found no significant 
effect of oxytocin on this or indeed on any of the three other tests that they used. Only when 
they combined one sub-element of the third domain of TASIT (sarcasm scores) with results 
from one of the other tests did they find a marginally significant effect.  
 
Although Woolley et al. (4) found no overall effect of oxytocin with RMET in healthy 
volunteers, in a post-hoc analysis they found an effect on the harder test items, partially 
replicating previous findings. For this, they selected test items which had attracted the lowest 
scores in the placebo condition, and compared the scores in the oxytocin condition. However, 
chance effects alone should produce a higher score for the ‘harder’ items identified in this 
way (‘regression to the mean’). Equally, chance effects should produce a lower score for the 
‘easier’ items – and from the Supplementary Material that they provided, this appears indeed 
to be the case.  
 
Quintana and Woolley argue that, although intranasal oxytocin produces only modest rises in 
CSF, these may still be functionally relevant. As detailed in our review, in animal studies, 
behavioural effects of intracerebroventricular oxytocin are only seen with injections that 
achieve very high CSF concentrations. In the only study measuring oxytocin in human CSF 
after intranasal application Striepens et al. (6)  found no increase after 45 or 60min, and only 
a modest (64%) increase after 75min, using a dose of 24 IU (6). As Quintana and Woolley 
argue that a much lower dose (8IU) may be more efficacious than 24IU, and as virtually all 
studies have tested subjects in a time window where Striepens et al. found no increase, we 
find it hard to see their case that CSF levels are relevant for the apparent effects of intranasal 
oxytocin. 
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In our review, we drew attention to the critical step of sample extraction when quantifying 
plasma oxytocin; measures of oxytocin in unextracted samples are much higher than, and do 
not correlate with, measures in extracted samples, and they appear not to reflect biologically 
active oxytocin. As Quintana and Woolley point out, this is not relevant to the issue of the 
effectiveness of intranasal oxytocin. However, these issues have become deeply entangled; 
for example, Woolley et al. (4) cite two studies of plasma oxytocin in their study rationale, 
both of which used the controversial assay of unextracted plasma.  
 
We congratulate Quintana et al. (7) for, for the first time in studies of intranasal oxytocin, 
including a group given oxytocin intravenously, and hope that this important control will 
become routine. Their study, involving recognition of facial emotions, used two doses of 
intranasal oxytocin (8IU and 24IU). There were no effects of either dose on happy ratings of 
ambiguous faces, angry or happy ratings of angry faces, or angry or happy ratings of happy 
faces. There was an apparent effect only on angry ratings of ambiguous faces, and only at the 
lower dose. This effect was significant on pairwise comparisons against both the placebo and 
the higher dose of intranasal oxytocin, but, importantly, not against i.v. oxytocin.  
 
We appreciate the importance of effective therapies for impaired social cognition, and the 
evidence from animal studies makes the central oxytocin systems a key target. At present, we 
believe that there are no robustly replicable measures of the effectiveness of intranasal 
oxytocin on social cognition, no understanding of its mechanism of action, and no certainty 
that effects are mediated by actions in the brain.  
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